Lollipop Sensor Detects Acetaminophen in Saliva
A prototype device returns acetaminophen readings from saliva in under two minutes, though it has not yet been validated for clinical use.
Updated on Nov. 6, 2026 in Diabetes
Researchers tested a lollipop-shaped sensor that detected acetaminophen in saliva from six adults in less than two minutes. The prototype has not yet been validated for clinical use.
Why it matters
Acetaminophen is found in many pain, cold, and flu medicines, and taking more than the recommended dose can cause serious harm, particularly liver damage. Because saliva concentrations can reflect blood concentrations, a device that analyses saliva at the point of care could offer a faster way to monitor the drug.
The test involved six adults who each took a 650 milligram acetaminophen dose, with saliva collected before and one hour after dosing and a result returned in under two minutes. The sample size is small, and the researchers have not yet compared the device's measurements with established methods in a larger participant group.
The players
University of Southern California
A private research university in Los Angeles, California, whose research team developed the Lollylab prototype.
The details
The Lollylab prototype consists of two joined plastic pieces coated with a red, peach-flavoured edible shell. Saliva passes through a paper-lined stem to a graphene sensor, where changes in electrical current indicate acetaminophen levels, avoiding the need to send a sample to a separate laboratory. The team, based at the University of Southern California, was inspired by CandyCollect, a lollipop-like saliva collection system whose samples are analysed elsewhere.
Timeline
November 6, 2026: Article published on the Lollylab acetaminophen saliva sensor study.
Health Landscape
The Lollylab prototype extends the CandyCollect concept, a lollipop-like saliva collection system whose samples are analysed in separate laboratories, by adding an on-device graphene sensor. This moves saliva-based drug monitoring toward point-of-care testing rather than sending samples off-site.
Anyone taking acetaminophen-containing medicines could eventually benefit from a quicker way to check drug levels, though the device is not yet available. Until then, staying within recommended doses remains the main safeguard against liver damage.
The takeaway
Point-of-care saliva testing could make drug monitoring faster and less invasive if larger studies confirm its accuracy. Readers should keep to labelled acetaminophen doses and check with a clinician before combining multiple medicines containing the drug.
Further reading
For related coverage, see Diabetes news and research.
Source note: This article includes information reported by Labmate online.
